60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report report published on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.86 on Friday. The stock has a market cap of $2.74 million, a price-to-earnings ratio of -0.18 and a beta of 4.52. 60 Degrees Pharmaceuticals has a one year low of $1.41 and a one year high of $35.99. The business’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $4.74.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.